bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

by Maria Zannes | Jan 13, 2025 | Press Releases

SAN ANTONIO, TX (Jan. 13, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath® Lung...

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

by Maria Zannes | Dec 17, 2024 | Press Releases

SAN ANTONIO, TX (Dec. 17, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET. The...

bioAffinity Technologies Set for Continued Expansion in 2025

by Maria Zannes | Dec 12, 2024 | Press Releases

Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues  SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage...

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

by Maria Zannes | Dec 5, 2024 | Press Releases

SAN ANTONIO, TX (Dec. 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint...

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

by Maria Zannes | Nov 14, 2024 | Press Releases

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024...

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

by Maria Zannes | Nov 4, 2024 | Press Releases

Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel SAN ANTONIO, Texas (Nov. 4, 2024) – bioAffinity Technologies,...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (119)
  • Publications (17)

Recent Posts

  • Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer May 8, 2025
  • bioAffinity Technologies Announces Closing of $3.25 Million Offering May 7, 2025
  • bioAffinity Technologies Announces Pricing of $3.25 Million Offering May 6, 2025
  • bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost April 17, 2025
  • bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 March 31, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.